AOC3 and eye inflammation: Neutralizing anti-VAP-1 antibodies and small-molecule VAP-1 inhibitors have been successfully utilized in experimental models to reduce adverse inflammatory reactions, among others, in acute skin, lung, liver, and eye inflammation, in chronic joint, gut, and brain inflammation, in severe systemic infections, in ischemia/reperfusion injury in different organs, in liver, lung, and kidney fibrosis, and in cancer.